Based on the domestic market, focus on making the HPV vaccine suitable for Chinese people

Cervical cancer is the second most common malignant tumor in breast cancer, with nearly 500,000 new cases worldwide and about 250,000 deaths. China has about 135,000 new cases each year, of which 80,000 people die on average. About 99.7 percent of cervical cancers are caused by HPV infection. As one of the important means to prevent cervical cancer, the HPV vaccine has high economic and social benefits.

Compared with the GSK bivalent vaccine that is currently listed in China, Kangleweishi uses its own technical strength to overcome technical difficulties and has added a type 58 virus antigen to the East Asian population in the HPV vaccine they developed. The company has significantly improved the preventive effect of the vaccine in China ––– with the prevention range going from 70-80 percent to more than 85 percent.

At the same time as the development of the HPV trivalent vaccine, Kangleweishi is accelerating the research on the second-generation HPV nine-valent vaccine. Compared with the trivalent vaccine, the nine-valent vaccine will greatly improve the prevention of cervical cancer, but the difficulty of research and development will also increase. Kangleweishi actively organizes scientific research, and now has made breakthrough, and plans to submit clinical trial applications this year.